收藏切换
Exploring the common mechanism of Yindan Xinnaotong soft capsule in the treatment of stroke and coronary heart disease through HIF1α-MMP9-mediated HIF1α signaling pathway
收藏切换
PDF
Jie GAO1, 2, Yi-feng DONG2, Si-meng WANG2, Ru-shang HE2, Ting-can JIANG2, Ming-jiang WU3, Hong-hua WU2, Xing LI4, Guan-wei FAN5, Yan ZHU2, Ming LV2, *
Acta Pharmaceutica Sinica | 2023, 58(6) : 1401 - 1411
Less
收藏切换
Acta Pharmaceutica Sinica | 2023, 58(6): 1401-1411
Special Reports: Research on Modernization of Traditional Chinese Medicine Based on Integrative Pharmacology
Exploring the common mechanism of Yindan Xinnaotong soft capsule in the treatment of stroke and coronary heart disease through HIF1α-MMP9-mediated HIF1α signaling pathway
Full
Jie GAO1, 2, Yi-feng DONG2, Si-meng WANG2, Ru-shang HE2, Ting-can JIANG2, Ming-jiang WU3, Hong-hua WU2, Xing LI4, Guan-wei FAN5, Yan ZHU2, Ming LV2, *
Affiliations
  • 1. College of Traditional Chinese Medicine, Hebei University, Baoding 071002, China
  • 2. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
  • 3. Zunyi Medical and Pharmaceutical College, Zunyi 563000, China
  • 4. Guizhou Bailing Group Pharmaceutical Co. Ltd., Guiyang 550000, China
  • 5. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
Published: 2023-06-12 doi: 10.16438/j.0513-4870.2023-0073
Outline
收藏切换

Coronary heart disease (CHD) and stroke are the most well-known cardiovascular diseases, which share many common pathological basis. Yindan Xinnaotong soft capsule (YDXNT) is a commonly used Chinese patent medicine in the treatment of stroke and CHD. However, its action of mechanism of co-treatment for stroke and CHD is still unclear. The aim of this study was to explore the common mechanism of YDXNT in co-treatment of CHD and stroke using network pharmacology, experimental verification and molecular docking. An integrated literature mining and databases of IPA, ETCM, HERB, Swiss Target Prediction, OMIM and GeneCards were used to screen and predict active ingredients and potential targets of YDXNT in co-treatment of CHD and stroke. The protein-protein interaction network, GO analysis and pathway analysis were analyzed by IPA software. The effect of YDXNT on core targets was verified by immunofluorescence. UPLC-QTOF/MS and molecular docking were used to screen and predict the main active constituents of YDXNT and their interactions with core targets. A total of 151 potential targets are predicted for YDXNT in co-treatment of CHD and stroke. Hypoxia-inducible factor-1α (HIF1α)-matrix metalloproteinase-9 (MMP9)-mediated HIF1α signaling pathway serves as one of the common mechanisms. YDXNT could reduce the increase of mitochondrial fluorescence intensity and the protein expression of HIF1α and MMP9 in HL-1 and HA induced by oxygen and glucose deprivation/reperfusion (OGD/R) in a dose-dependent manner. Baicalin may be the material basis for treating stroke and CHD with YDXNT. In conclusion, the HIF1α signaling pathway is one of the common key mechanisms of YDXNT in the co-treatment of stroke and CHD. The study provides support and basis for the in-depth scientific connotation of the traditional Chinese medicine theory of "same treatment to different diseases".

Yindan Xinnaotong soft capsule  /  coronary heart disease  /  stroke  /  HIF1α signaling pathway  /  same treatment to different diseases
Jie GAO, Yi-feng DONG, Si-meng WANG, Ru-shang HE, Ting-can JIANG, Ming-jiang WU, Hong-hua WU, Xing LI, Guan-wei FAN, Yan ZHU, Ming LV. Exploring the common mechanism of Yindan Xinnaotong soft capsule in the treatment of stroke and coronary heart disease through HIF1α-MMP9-mediated HIF1α signaling pathway[J]. Acta Pharmaceutica Sinica, 2023 , 58 (6) : 1401 -1411 . DOI: 10.16438/j.0513-4870.2023-0073
Year 2023 volume 58 Issue 6
PDF
242
111
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2023-0073
  • Receive Date:2023-01-27
  • Online Date:2025-11-21
  • Published:2023-06-12
Article Data
Affiliations
History
  • Received:2023-01-27
  • Revised:2023-05-23
Funding
Affiliations
    1. College of Traditional Chinese Medicine, Hebei University, Baoding 071002, China
    2. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
    3. Zunyi Medical and Pharmaceutical College, Zunyi 563000, China
    4. Guizhou Bailing Group Pharmaceutical Co. Ltd., Guiyang 550000, China
    5. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2023-0073
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT